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Coronary Magnetic
Resonance Imaging
Coming of Age*
Warren J. Manning, MD, Raymond H. Chan, MD
Boston, Massachusetts
The natural evolution of an imaging technology includes:
1) demonstration in phantoms and animal models; 2) testing in
highly selected populations with defined disease; 3) single-
center assessment in broader populations; 4) multicenter trials
to define “real world” accuracy, and finally; and 5) assess-
ment for prognosis/clinical management. It has been nearly
2 decades since the first reports of clinical coronary magnetic
resonance imaging (MRI) in comparison with x-ray coro-
nary angiography (1). Since then, there have been numerous
technical advances in both hardware and software, with
migration to whole-heart steady-state free precession with-
out (2) and with (3) contrast as well as higher field coronary
MRI (4). Multicenter trials in comparison with x-ray
coronary angiography have also been performed both in the
United States and Europe (5) and in Japan (6). Despite
these advances, coronary MRI remains a niche application
offered only at selected cardiac magnetic resonance (CMR)
centers, often for patients with suspected anomalous or
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multivessel coronary artery disease (CAD). Its role in the
diagnosis of CAD has not been widely embraced by the
clinical cardiologic community. Though comparative stud-
ies suggest equivalent diagnostic yield for the detection of
angiographic CAD (7,8) with superiority of coronary com-
puted tomography angiography (CTA) for successful image
acquisition and superiority of coronary MRI for accuracy in
patients with high calcium scores (9), coronary CTA has
more widely penetrated the clinical arena due to the
technical ease of and much faster data acquisition and lower
patient burden—despite CTA’s need for iodinated contrast
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of this paper to disclose.volumes similar to invasive x-ray angiography and exposure
to ionizing radiation. It has been well recognized that
conventional x-ray angiography is a suboptimal gold stan-
dard for the assessment of CAD. Indeed, fractional flow
reserve is now considered a superior discriminator for the
identification of lesions that warrant mechanical percutane-
ous intervention (10).
Even though diagnostic imaging tests are performed to
identify those with CAD, there is also value in excluding
disease. For those without disease on a noninvasive or
invasive diagnostic test, clinicians want to know the “war-
ranty period” of a “normal” test result. For stress testing, this
is 2 years for nondiabetic patients (11), but only 1 year for
patients with diabetes. For epicardial calcium on cardiac CT
and for coronary CTA, the prognosis of “zero” calcium
score or a normal coronary CTA is excellent (12). Similar
data have been unknown for coronary MRI.
In this issue of the Journal, Yoon et al. (13) report for the
first time on the moderate-term prognostic value of coro-
nary MRI. A total of 207 patients with suspected CAD
underwent noncontrast, free-breathing whole-heart steady-
state free precession coronary MRI in 2007 and 2008 are
followed for a median of 25 months. The most common
indication for coronary MRI was chest pain. Forty-one
percent had significant CAD on coronary MRI, of whom
there were 10 cardiac events, including 5 severe events
(cardiac death: n  1, unstable angina: n  4), for an
annualized event rate of 3.9%. Of the 123 (60%) without
significant coronary disease on coronary MRI, none under-
went revascularization and there were no cardiac events
(annualized event rate: 0%). There was 1 noncardiac death
due to malignancy. The presence of a stenosis on coronary
MRI was the most significant predictor of all cardiac events.
Although a small study from experienced CMR investi-
gators, these data do provide the first insight regarding the
warranty period of a normal coronary MRI and add to the
growing prognostic data regarding multiparameter CMR,
including late gadolinium enhancement for ischemic and
nonischemic cardiomyopathies (14–16) and volumetric left
ventricular ejection fraction (17). Though Yoon et al.
reported solely on coronary MRI, comprehensive CMR
examinations provide information far beyond coronary ar-
tery lumen assessment. At our institution, coronary CMR is
most commonly performed in combination with assessment
of biventricular volumes and regional/global systolic func-
tion and late gadolinium enhancement. The recent CE-
MARC (Clinical Evaluation of Magnetic Resonance Im-
aging in Coronary Heart Disease) study (18) demonstrated
the superior accuracy of multiparameter CMR versus phar-
macologic radionuclide single-photon emission CT imaging
for 759 patients with suspected CAD. Prognosis data from
this prospective multiparameter CMR study are eagerly
awaited and offer the opportunity to examine prognostic
data of individual components of the CMR examination.
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Coronary MRI December 4, 2012:2323–4Finally, we need some reality testing. CMR is moving
into the mainstream of clinical cardiology, but the study of
Yoon et al. (13) does not provide a license to expand
coronary CMR testing for purposes of prognosis in patients
concerned about their risk of CAD or even those with
multiple CAD risk factors. These patients were not studied.
As with screening exercise tests in high risk asymptomatic
populations, applications of testing in what may seem
“logical” populations does not always result in improved
prognosis (19). Even though coronary CMR testing is
noninvasive and has minimal patient risk, there are tremen-
dous potential costs to our healthcare system with the
introduction of novel high-technology tests. We can no
longer afford to simply add these new imaging technologies
to our existing evaluation paradigms. Will the prognostic
value of a normal coronary MRI (or comprehensive CMR
study or coronary CTA or stress) myocardial perfusion be
superior to less intense technologies (e.g., stable symptoms
and able to exercise 10 metabolic equivalents of oxygen
consumption without symptoms or ischemia on a nonim-
aging exercise stress test)? We need to rigorously assess new
technologies using decision analysis methods and identify
clinical pathways in which these new technologies will
displace rather than simply add to existing management
strategies. Yoon et al. have provided important information
with regard to the prognosis of a normal coronary MRI in
patients with suspected CAD. Now we need to confirm
their findings in larger multicenter studies and, most im-
portantly, learn how to responsibly integrate their findings
into the management of patients with suspected CAD in a
cost-efficient manner. In so doing, coronary MRI will
emerge from its adolescence to define its role in clinical
cardiology.
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